<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800081</url>
  </required_header>
  <id_info>
    <org_study_id>2020A-247</org_study_id>
    <nct_id>NCT04800081</nct_id>
  </id_info>
  <brief_title>Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension</brief_title>
  <official_title>Effect of Sacubitril/Valsartan on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LanZhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy of Sacubitril/Valsartan in the treatment of perimenopausal&#xD;
      hypertensive patients, as well as the difference between the antihypertensive efficacy and&#xD;
      valsartan, the therapeutic effect of its exposure to different factors and the protection of&#xD;
      target organs.To provide reference for the clinical treatment of perimenopausal hypertension&#xD;
      patients with shakubactrivalsartan.&#xD;
&#xD;
        1. To evaluate the effects of Sacubitril/Valsartan on urinary microalbumin and pulse wave&#xD;
           velocity in perimenopausal hypertension patients.&#xD;
&#xD;
        2. To evaluate the clinical application of Sacubitril/Valsartan in the treatment of&#xD;
           perimenopausal hypertension, so as to improve the blood pressure management ability and&#xD;
           control rate of patients with such hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 264 cases of perimenopausal patients with essential hypertension who were admitted&#xD;
      to Department of Cardiology, Second Hospital of Lanzhou University,from January, 2020 to&#xD;
      March,2021 will be enrolled and randomized to receive once-daily treatment with 100-400 mg of&#xD;
      Sacubitril/Valsartan or 80-320 mg of Valsartan.The general information, menstrual history,&#xD;
      cardiac ultrasound, urinal-renal function, PWV, baseline blood pressure, post-medication&#xD;
      blood pressure, whether to use antihypertensive drugs and the type of antihypertensive drugs&#xD;
      of the patients were enrolled.After 12 weeks of drug intervention, left ventricular mass&#xD;
      indexwere measured by cardiac ultrasound, PWV, urinary microalbinin, 24-hour ambulatory blood&#xD;
      pressure monitoring, biochemical indicators will be collected.SPSS22.0 statistical software&#xD;
      was used for statistical analysis of PWV, urinary microalbumin, blood pressure and other&#xD;
      results by paired data t-test, and the chi-square test was used for non-count data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">July 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of 264 cases of perimenopausal patients with essential hypertension who were admitted to Department of Cardiology, Second Hospital of Lanzhou University,from January, 2020 to March,2021 will be enrolled and randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan or 80-320 mg of Valsartan.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure，24 hour automatic blood pressure monitoring，home blood pressure monitoring，Office blood pressure</measure>
    <time_frame>Evaluation at 12 weeks of treatment will be reported</time_frame>
    <description>Changes in this major indicators were detected before and after drug treatment in both groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary microalbuminuria</measure>
    <time_frame>Evaluation at 12 weeks of treatment will be reported</time_frame>
    <description>Changes in this major indicators were detected before and after drug treatment in both groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pulse wave velocity</measure>
    <time_frame>Evaluation at 12 weeks of treatment will be reported</time_frame>
    <description>Changes in this major indicators were detected before and after drug treatment in both groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ventricular mass indexwere measured by cardiac ultrasound</measure>
    <time_frame>Evaluation at 12 weeks of treatment will be reported</time_frame>
    <description>Changes in this major indicators were detected before and after drug treatment in both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During the drug intervention up to 30 days,60 days and 80days,it will bereported in the final.</time_frame>
    <description>such as arrhythmology，dizzy， headache，edema，cough.Other incidents are even more serious</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive once-daily treatment with 80-320 mg of Valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril/Valsartan</intervention_name>
    <description>Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.</description>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <other_name>LCZ696</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with essential hypertension（SBP&gt;140 and &lt;180 mmHg, and/or DBP&gt;90 and &lt;110&#xD;
             mmHg)）were diagnosed according to the hypertension diagnostic criteria of the Chinese&#xD;
             Guidelines for Hypertension (2018 Revised Edition)；&#xD;
&#xD;
          2. Female aged 45-55 years old and meeting the perimenopausal criteria in the STRAE+10;&#xD;
&#xD;
          3. No other complications, no treatment or ongoing antihypertensive therapy (SBP ≥140mmHg&#xD;
             or Diastolic BP ≥90mmHg)；&#xD;
&#xD;
          4. Agree to participate in the study and sign the informed consent；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary hypertension；&#xD;
&#xD;
          2. History of angioedema；&#xD;
&#xD;
          3. Heart failure NYHA grade III or above (excluding grade III)；&#xD;
&#xD;
          4. Liver and kidney dysfunction (ALT or AST≥ three times the upper limit of normal value,&#xD;
             that is, ALT≥120U/L,AST≥120U/L, creatinine clearance &lt; 30ml/min);&#xD;
&#xD;
          5. Hyperkalemia (serum potassium ≥5.5mmol/L);&#xD;
&#xD;
          6. Moderate or above anemia (HGB≤90g/L);&#xD;
&#xD;
          7. Bilateral renal artery stenosis;&#xD;
&#xD;
          8. History of stroke;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Pei, MD</last_name>
    <phone>+86-0931-17318717573</phone>
    <email>peiy19@lzu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Second Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>GuSu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Pei, MD</last_name>
      <phone>+86-0931-17318717573</phone>
      <email>peiy19@lzu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LanZhou University</investigator_affiliation>
    <investigator_full_name>Ying Pei</investigator_full_name>
    <investigator_title>house physician</investigator_title>
  </responsible_party>
  <keyword>perimenopausal</keyword>
  <keyword>hypertensive</keyword>
  <keyword>Sacubitril/Valsartan</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>urinary microalbuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

